The global plasma protease C1-inhibitor treatment market accounted for USD 4.62 billion in 2023 and is expected to reach at USD 29.11 billion by 2034 with a CAGR of 18.21% during the forecast period 2024-2034. The market will grow as a result of rising government support and reimbursement policies, growing incidence of hereditary angioedema (HAE), advancements in biotechnology and pharmacology, and strategic alliances and collaborations.
A rare genetic condition known as hereditary angioedema is characterized by recurrent episodes of swelling in different body areas. A vital treatment for controlling acute episodes and averting their recurrence is C1-INH replacement therapy. The market for C1-INH therapy is anticipated to grow as knowledge of HAE grows and diagnostic tools advance. For instance, Pharming Group reported positive topline data in January 2022 from their Phase 3 trial assessing the safety and effectiveness of RUCONEST® (recombinant human C1 esterase inhibitor) for the treatment of pediatric patients' acute hereditary angioedema (HAE) attacks.
By drug type, the C1-inhibitors segment accounted for the highest revenue-grossing segment in the global plasma protease C1-inhibitor treatment market in 2023 owing to the increasing prevalence of hereditary angioedema (HAE) and expanding indications for C1-inhibitor therapies, driving demand and market growth. For instance, CSL Behring stated in November 2022 that a Phase 3 clinical trial for CSL830, a novel C1-INH replacement medication, would begin in November 2022 to treat attacks of hereditary angioedema (HAE). Additionally, the selective bradykinin B2 receptor antagonist segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising recognition of its efficacy in managing acute attacks of hereditary angioedema (HAE) and ongoing advancements in its development, enhancing its therapeutic potential.
By dosage, the injectable segment accounted for the highest revenue-grossing segment in the global plasma protease C1-inhibitor treatment market in 2023 owing to the increased preference for rapid and reliable administration, along with the established efficacy and safety profile of injectable formulations, driving their widespread adoption. For instance, Takeda reported the good topline results of their Phase 3 trial in March 2023, which assessed the safety and effectiveness of TAKHZYRO® (lanadelumab) in preventing attacks of hereditary angioedema (HAE). Additionally, the lyophilized segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for lyophilized formulations due to their longer shelf life, ease of storage, and potential for extended stability, meeting the need for convenient and stable treatment options.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global plasma protease C1-inhibitor treatment market in 2023 owing to the prevalence of hereditary angioedema (HAE) patients seeking acute care in hospital settings, facilitating greater accessibility and utilization of C1-inhibitor treatments through hospital pharmacies. For instance, BioCryst Pharmaceuticals reported in October 2022 that a Phase 3 clinical trial assessing the oral Factor D inhibitor BCX9930 for the treatment of cold agglutinin disease (CAD) had begun. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased adoption of online purchasing trends for healthcare products, convenience, and accessibility, along with expanding internet penetration and digital healthcare platforms, driving growth in the online pharmacies segment.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of hereditary angioedema (HAE), well-established healthcare infrastructure, and early adoption of advanced therapies, contributing to the dominance of the North American region in the plasma protease C1-inhibitor treatment market. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness of hereditary angioedema (HAE), improving healthcare infrastructure, and rising healthcare expenditure, driving the demand for plasma protease C1-inhibitor treatments in the Asia Pacific region. For instance, Centogene AG stated in October 2022 that it was expanding its partnership with Alnylam Pharmaceuticals to offer genetic testing services to patients suffering from hereditary angioedema (HAE).
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
A rare genetic condition known as hereditary angioedema is characterized by recurrent episodes of swelling in different body areas. A vital treatment for controlling acute episodes and averting their recurrence is C1-INH replacement therapy. The market for C1-INH therapy is anticipated to grow as knowledge of HAE grows and diagnostic tools advance. For instance, Pharming Group reported positive topline data in January 2022 from their Phase 3 trial assessing the safety and effectiveness of RUCONEST® (recombinant human C1 esterase inhibitor) for the treatment of pediatric patients' acute hereditary angioedema (HAE) attacks.
By drug type, the C1-inhibitors segment accounted for the highest revenue-grossing segment in the global plasma protease C1-inhibitor treatment market in 2023 owing to the increasing prevalence of hereditary angioedema (HAE) and expanding indications for C1-inhibitor therapies, driving demand and market growth. For instance, CSL Behring stated in November 2022 that a Phase 3 clinical trial for CSL830, a novel C1-INH replacement medication, would begin in November 2022 to treat attacks of hereditary angioedema (HAE). Additionally, the selective bradykinin B2 receptor antagonist segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising recognition of its efficacy in managing acute attacks of hereditary angioedema (HAE) and ongoing advancements in its development, enhancing its therapeutic potential.
By dosage, the injectable segment accounted for the highest revenue-grossing segment in the global plasma protease C1-inhibitor treatment market in 2023 owing to the increased preference for rapid and reliable administration, along with the established efficacy and safety profile of injectable formulations, driving their widespread adoption. For instance, Takeda reported the good topline results of their Phase 3 trial in March 2023, which assessed the safety and effectiveness of TAKHZYRO® (lanadelumab) in preventing attacks of hereditary angioedema (HAE). Additionally, the lyophilized segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for lyophilized formulations due to their longer shelf life, ease of storage, and potential for extended stability, meeting the need for convenient and stable treatment options.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global plasma protease C1-inhibitor treatment market in 2023 owing to the prevalence of hereditary angioedema (HAE) patients seeking acute care in hospital settings, facilitating greater accessibility and utilization of C1-inhibitor treatments through hospital pharmacies. For instance, BioCryst Pharmaceuticals reported in October 2022 that a Phase 3 clinical trial assessing the oral Factor D inhibitor BCX9930 for the treatment of cold agglutinin disease (CAD) had begun. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased adoption of online purchasing trends for healthcare products, convenience, and accessibility, along with expanding internet penetration and digital healthcare platforms, driving growth in the online pharmacies segment.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of hereditary angioedema (HAE), well-established healthcare infrastructure, and early adoption of advanced therapies, contributing to the dominance of the North American region in the plasma protease C1-inhibitor treatment market. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness of hereditary angioedema (HAE), improving healthcare infrastructure, and rising healthcare expenditure, driving the demand for plasma protease C1-inhibitor treatments in the Asia Pacific region. For instance, Centogene AG stated in October 2022 that it was expanding its partnership with Alnylam Pharmaceuticals to offer genetic testing services to patients suffering from hereditary angioedema (HAE).
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Drug Type, Dosage, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement
Segmentation: Plasma Protease C1-Inhibitor Treatment Market Report 2023 - 2034
Plasma Protease C1-Inhibitor Treatment Market Analysis & Forecast by Drug Type 2023 - 2034 (Revenue USD Bn)
- C1-inhibitors
- Kallikrein Inhibitor
- Selective Bradykinin B2 Receptor Antagonist
Plasma Protease C1-Inhibitor Treatment Market Analysis & Forecast by Dosage 2023 - 2034 (Revenue USD Bn)
- Lyophilized
- Injectable
Plasma Protease C1-Inhibitor Treatment Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Plasma Protease C1-Inhibitor Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Plasma Protease C1-Inhibitor Drug Type Market: Drug Type Estimates & Trend Analysis
8. Plasma Protease C1-Inhibitor Drug Type Market: Dosage Estimates & Trend Analysis
9. Plasma Protease C1-Inhibitor Drug Type Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Plasma Protease C1-Inhibitor Drug Type Market
12. Europe Global Plasma Protease C1-Inhibitor Drug Type Market
13. Asia Pacific Global Plasma Protease C1-Inhibitor Drug Type Market
14. Latin America Global Plasma Protease C1-Inhibitor Drug Type Market
15. MEA Global Plasma Protease C1-Inhibitor Drug Type Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- CSL Behring
- Takeda Pharmaceutical Company Limited
- Pharming Group N.V.
- BioCryst Pharmaceuticals Inc.
- Shire (now part of Takeda)
- Pharming Healthcare Inc.
- Adverum Biotechnologies Inc.
- Centogene AG
- Lev Pharmaceuticals (acquired by ViroPharma)
- Sanquin
- Octapharma AG
- Biotest AG
- Beijing Four Rings Biopharmaceutical Co. Ltd.
- GC Pharma
- Dyax Corp.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | October 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 4.62 Billion |
| Forecasted Market Value ( USD | $ 29.11 Billion |
| Compound Annual Growth Rate | 18.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
